Antonio Lee, Ph.D., CEO

Oct. 11 | 5:00pm | Ecolab Life Sciences Ballroom 

Boston, MA


MEDIPOST is found in 2000 and headquartered in Korea and became a public company in 2005 listed in KOSDAQ with around 300 employees. The wholly-owned U.S. subsidiary (MEDIPOST Inc.) is located in Boston, MA and the Japanese subsidiary (EVASTEM Co.) in Tokyo. In 2022, MEDIPOST has acquired a stake-holding in OmniaBio Inc. (a CGT CDMO based in Ontario Canada) in partnership with CCRM in Toronto. MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by South Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit).” To date, over 27,000 patients have been treated on the market with an excellent long-term safety and efficacy profile. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions